AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02415452 — intervention group
Intervention type: PROCEDURE
Intervention: drug-eluting stent implantation
Description: The DES contains Firebird , sirolimus-eluting stents, paclitaxel-eluting stents , or zotarolimus-eluting stents . Unfractionated heparin was used during percutaneous coronary intervention .A loading dose of 300 mg clopidogrel was given to all patients prior to PCI, followed by a maintenance dose of 75 mg daily for 12 months before it was stopped.
Study NCT05443152 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fetal movement and position tracking training
Description: In the first stage, pregnant women were trained to implement fetal movement count and position tracking. The training was provided face to face and lasted 30-45 minutes. How to determine the position of the fetus and I. and II. Leopold maneuvers are also taught. In the second stage, the pregnant women were interviewed twice a week by telephone.Thus, it was provided that pregnant women had fetal tracked at least once a day, at any time of the day, when the fetus was awake and most active, in a suitable position and a comfortable environment, for at least 15-20 minutes continuously for four weeks. Pregnant women phoned the researcher when they wanted. At the same time, the participants continued to their routine prenatal care.
Study NCT02093559 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief counseling Intervention
Description: The brief counseling intervention will utilize MI and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address HIV risk behaviors and determine readiness for change in substance use.
Study NCT01423032 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: 100 mg/m² iv, day 1+2, q4w
Study NCT01423032 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Description: 25 mg/m² iv, days 1-5, q4w
Study NCT02977637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Feraheme MRI/MRA
Study NCT00522873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)
Description: One capsule \[0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)\] per day taken orally for 13 cycles (28 days per cycle).
Study NCT05223270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wound dressing under the NIMV mask
Description: wound dressing under the NIMV mask
Study NCT03369418 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Alpha-Stim Active
Description: The study device is a safe, commercially available take-home cranial electrotherapy stimulation device that applies an electrical current to a subject's head to treat anxiety, depression or insomnia
Study NCT03369418 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Alpha-Stim Inactive
Description: The study device given to the inactive group will be identical to the active except the electrodes attached to the device will be inactive. The device will not transmit anything when turned on because the electrodes are inactive.
Study NCT03586713 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: light induced fluorescence camera
Description: The light induced fluorescence intraoral camera works with a visible blue light frequency (wavelength 450 nm) for the illumination of the dental surface and produces an overlapping image of the green fluorescence image on the image of the white light. The green fluorescence image is considered an indicator of healthy dental tissues. The colour of the fluorescence signal is green when the dentin is healthy. The healthy enamel is blue due to the scattered green light of the dentin, despite the lack of a fluorescence signal. On the other hand, caries can be easily detected by dark red fluorescence.
Study NCT03947619 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Impella CP® placement prior to reperfusion with Primary PCI
Description: Subjects randomized to the experimental arm, will undergo Impella CP® placement through a femoral arterial sheath and the Impella device will be activated to unload the left ventricle.
Study NCT02702466 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPA Therapy
Description: Immersion bath and shower ( 1 treatment ) Underwater shower with localized massage on the painful area ( 1 treatment ) or equivalent underwater massage Illutations ( 1 treatment ) or equivalent ( poultice ) Mobilization Pool ( 1 care) Education to exercise
Study NCT02702466 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: SPA Therapy
Description: Immersion bath and shower ( 1 treatment ) Underwater shower with localized massage on the painful area ( 1 treatment ) or equivalent underwater massage Illutations ( 1 treatment ) or equivalent ( poultice ) Mobilization Pool ( 1 care) Education to exercise
Study NCT01441843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorazepam
Description: Once 1mg \<75kg body weight, 1.5mg 75kg and >75kg body weight, IV, before surgery
Study NCT01441843 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NaCl 0.9% (Sodium Chloride)
Description: Once 1ml \<75kg body weight, 1.5ml 75kg or >75kg body weight, IV, before surgery
Study NCT02750189 — intervention group
Intervention type: OTHER
Intervention: Direct cost
Description: Money spent to treat COPD in medical institute based on HIRA
Study NCT02750189 — intervention group
Intervention type: OTHER
Intervention: Indirect cost
Description: extra-expanses excluding hospital fees
Study NCT04581265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin
Description: Participants received a single dose of albumin-bound paclitaxel (nab-PTX) 270mg/m2/d, administered intravenously (IV) on Day 1; Ifosfamide 1.2g/m2/d administered intravenously (IV) on Day 2-6; Cisplatin 20mg/m2/d administered intravenously (IV) on Day 2-6.
Study NCT05572866 — intervention group
Intervention type: OTHER
Intervention: COVID-19 pandemic
Description: To retrospectively review the surgical volume across 2019-2022 to see the impact of the COVID-19 pandemic.
Study NCT04348266 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Description: Radiofrequency ablation is a device that can generate the heat from radiofrequency for tissue ablation. RFA is a standard treatment for Barrett' esophagus and high grade dysplasia in esophagus.
Study NCT02040649 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-sedation
Description: Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
Study NCT02040649 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control, sedation (propofol, midazolam)
Description: Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
Study NCT00964496 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Patients were randomly assigned to receive a four-month course of 25 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang-zhou, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
Study NCT00964496 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Iron
Description: Patients were randomly assigned to receive a four-month course of 100 mg of iron (Pharmaceutical Co., Ltd. of Nanjing, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
Study NCT01246427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BRN01
Description: 2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
Study NCT01246427 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
Study NCT03687788 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Laughter Therapy
Description: Laughter therapy program was composed of four steps. The first step, which took 10 minutes, had warm-up exercises including gentle stretching and hand clapping. The second step, which included deep breathing exercises and hand clapping, took 5 minutes. The third step involved children's games and laughter exercises. In this step, the most common laughter exercises were milkshake laughter, bugi bugi laughter techniques, lion laughter, cell phone, hot soup laughter, hug laughter, bird laughter, dialogue with nonsense, speech exercises, laugh at one's own aches and pains exercises, argument laughter, brushing teeth and mouthwash exercises. The sessions included a combination of different laughter exercises. This step took 15 minutes. The last step, which included wishes and resting by breathing, took 10 minutes.
Study NCT03564288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-G-801
Description: SKI-G-801 is administered as an IV infusion over 10 minutes
Study NCT04315155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Doublet Regimen Dose levels for Part 1:~Belinostat Dose Level 1 (starting dose) 500 mg/m2 Dose Level 2 750 mg/m2 Dose Level 3 1000 mg/m2
Study NCT04315155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Doublet Regimen Dose levels for Part 1 Nivolumab Dose Level 1 (starting dose) 360 mg Dose Level 2 360 mg Dose Level 3 360 mg
Study NCT04315155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipilimumab
Description: Triplet and Doublet Regimen Dose Levels for Phase 2 Ipilimumab Doublet Dose n/a Triplet Dose 1 mg/kg
Study NCT04315155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: Triplet and Doublet Regimen Dose Levels for Phase 2 Nivolumab Doublet Dose 360 mg IV Triplet Dose 3 mg/kg
Study NCT04315155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belinostat
Description: Triplet and Doublet Regimen Dose Levels for Phase 2 Belinostat Doublet Dose RP2D Triplet Dose RP2D
Study NCT03255902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting classes
Description: Parenting Classes:The Incredible Years curriculum
Study NCT00921271 — intervention group
Intervention type: DEVICE
Intervention: Monitoring of StO2
Description: Monitoring of lower limb anterior compartment StO2, taking measurements on an hourly basis for the duration of the study protocol.
Study NCT03145740 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive F.O.T.T.®
Description: Therapeutic F.O.T.T.® intervention provided by Occupational Therapists (OTs). The intervention consists of positioning the patient, and giving sensory input to the hands and face in order to stimulate and facilitate swallowing of saliva or small amounts of food and drink, if considered safe.
Study NCT03145740 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Unspecific Stimulation of face and mouth
Description: The intervention consists of positioning the patient and either washing his face, the hands, or brushing teeth, apply lipbalm, with no specific stimulation or facilitation of swallowing
Study NCT03360435 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Patch MD MultiVitamin Plus patch
Description: The transdermal patch contains vitamins A, D, E, K2, C, thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folic acid, cyanocobalamin, calcium, iron, phosphorous, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, potassium, chloride, and boron.
Study NCT03091725 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery
Description: A bariatric surgery procedure which will help individuals achieve 16-18% weight loss
Study NCT03091725 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Very low-calorie diet
Description: Subjects will meet with a dietitian and/or behaviorist over 4-6 months to lose 16-18% of their body weight.
Study NCT00956735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pistachio
Description: 3.0 oz (2 servings) of roasted and salted or unsalted pistachios
Study NCT02305030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067
Study NCT02305030 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Study NCT02914639 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SF0166 Topical Ophthalmic Solution
Study NCT03282058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Silastic Stent
Description: The silastic stent is a splint made of silicone.
Study NCT01936571 — intervention group
Intervention type: OTHER
Intervention: Blood samples
Description: Blood samples, that were collected, processed and stored in the Maastro biobank in a standardized way, will be used to measure CRP, LDH, Osteopontin, CA-9 IL-6, IL-8, CEA, CYFRA 21-1, and α-2M. Clinical data will be retrieved from the electronic medical files.
Study NCT03439501 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: avelumab
Description: * Study drug: Avelumab (PD-L1 inhibitor; MSB0010718C)~* Dosage: 10 mg per body weight (kg) of a subject every two weeks~* One cycle consists of two injection of avelumab (28 days).~* The treatment cycle will be repeated until progression of disease or unacceptable toxicity and dose adjustments are permitted for patients who are unable to tolerate the side effects of drugs within each cycle.
Study NCT00304174 — intervention group
Intervention type: BEHAVIORAL
Intervention: Motivation to eat
Description: Participants will use a computer program to earn food (a yogurt shake) by tapping on the keyboard. More taps on the keyboard will result in a larger amount of food earned by the end of the day. Once experimentation is complete on Day 1, participants will be instructed to eat as much as they can. On Days 2 and 3, participants will be given a small serving of the yogurt shake prior to beginning the computer task. Following the computer task, they will be instructed to either eat until they are comfortable (without restricting or binging), or eat as much as they can.
Study NCT03078322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-101
Description: Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Study NCT03078322 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
Study NCT01900158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphinex, Gemcitabine and Cisplatin
Description: Amphinex administration on day 0, followed by gemcitabine administration (1000 mg/m2) and laser light application (652 nm) on day 4 followed by systemic gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) given on Day 1 and Day 8 of each 21-day cycle, for up to a total of eight cycles. Either one or two PCI treatments (Amphinex, Gemcitabine and intraluminal laser light of 652nm) during the 8 cycles of chemotherapy
Study NCT04122365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest Wall Mobilization Program
Description: Soft tissue therapy and joints mobilization
Study NCT04122365 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Routine limbs exercises and education
Study NCT01295359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ground Walking Program
Description: The patients will walk on a corridor, for 40min, once a day. The speed will be controlled through a metronome, that will be programed to a frequency of steps/min determinated as 80% of the mean frequency of steps performed in six minutes walk test of that day. The 40min will be divided in 3min of walk and 2min of rest, totalizing 24min of exercise and 16min of rest. Furthermore, these patients, in sitting position, will receive orientation to do calm and slow inspirations and expirations, associated with pursed lips expiration. They will try to maintain its Respiratory Rate in 6bpm, during four minutes.
Study NCT05730296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: 10 rTMS sessions combined with cognitive training
Study NCT05730296 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: 10 rTMS sessions
Study NCT05730296 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: 10 sham coils sessions without cognitive training
Study NCT01726894 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation
Study NCT03301883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab will be administered as per the schedule specified in the arm description.
Study NCT03301883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NSAIDs
Description: Participants may receive NSAIDs up to the maximum recommended stable daily dose. Study protocol does not enforce any particular NSAID.
Study NCT03301883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSs
Description: Participants may receive CSs at a stable dose of 30 milligrams per day (mg/day) or 0.5 milligrams per kilogram per day (mg/kg/day), whichever is less. Study protocol does not enforce any particular CS.
Study NCT03301883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Participants may receive MTX at a stable dose of less than or equal to (\</=) 20 milligrams per square meter (mg/m\^2).
Study NCT03268785 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intraoperative identification method
Description: After needle pucture of suspicious nodes, Diff-quik staining was used to distinct lymph nodes and parathyroid glands. PTH test assay was used for parathyroid identification. Postoperative HE staining were applied as golden standard.
Study NCT02414815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Monophasic action potential(MAP) catheter
Description: After ordinary procedure for electrophysiologic study or catheter ablation, the investigators will replace conventional catheter to monophasic action potential (MAP) recording catheter through right femoral sheath. MAP recording catheter is introduced to endocardial surface of atrium, and we record atrial MAP at variable pacing cycle lengths: steady state cycle lengths of 600, 400, 300, 240, 220, 240, 260, 300, 400 and 600 ms. At each cycle length, pacing was applied for 20 sec. It takes less than 5 min to acquire MAP recordings.
Study NCT02451085 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: training with video therapy
Description: training with video therapy
Study NCT02451085 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: conventional exercise
Description: training in conventional way
Study NCT03892616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894 (B)
Description: Tablet formulation 2 (TF2a), fed
Study NCT03892616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894 (C)
Description: Tablet formulation 2 (TF2a), fasted
Study NCT03892616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894 (D)
Description: Tablet formulation 2 (TF2b), fed
Study NCT03892616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894 (E)
Description: Tablet formulation 2 (TF2b), fasted
Study NCT03892616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894 (A)
Description: Tablet formulation 1 (TF1), fed
Study NCT04555395 — intervention group
Intervention type: OTHER
Intervention: survival rates
Description: survival rates
Study NCT03573414 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: raspberry powder, milled flaxseed and soy milk
Description: * The participants will consume a breakfast consisting of 30 g of milled flaxseed, 40 g of raspberry powder and 250 ml of soy milk for 3 days~* The participants will provide blood and urine samples
Study NCT00971802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845 or Placebo
Description: PF-03882845 20 mg or Placebo, daily for 10 days.
Study NCT00971802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845 or Placebo
Description: PF-03882845 60 mg or Placebo, daily for 10 days.
Study NCT00971802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845 or Placebo
Description: PF-03882845 120 mg or Placebo, daily for 10 days.
Study NCT00971802 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03882845 or Placebo
Description: PF-03882845 185 mg or Placebo, daily for 10 days.
Study NCT04562454 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific diet
Description: use a specific diet in different days with CGM to konw GI of different food in diabetes
Study NCT03831477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venus Viva
Description: The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
Study NCT03831477 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Venus Viva
Description: The Venus Viva™ is a non-invasive medical aesthetic device, intended for use in dermatologic and general surgical procedures, requiring ablation and resurfacing of the skin, using the Viva applicator.
Study NCT03309566 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz, tenofovir disoproxil fumarate and emtricitabine
Description: Two period administration of a formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.